Although detection of cell-surface vimentin in cancer cells has been demonstrated in different studies [58, 59], its role as a biomarker by using a monoclonal antibody 84-1 for detecting CTC from blood of cancer patients affected by carcinoma as well as sarcoma has been established [57]. The gene discussed is VIM; the disease is cancer.